Hemophilia Treatment Market, By Product (Recombinant coagulation factor concentrates, Plasma derived coagulation factor concentrates, Antifibrinolytic agents, and Desmopressin), By Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C) By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospitals, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030

Report Code: PMI12119 | Publish Date: March 2024 | No. of Pages: 189

Global Hemophilia Treatment Market By Overview

Hemophilia is a rare inherited genetic condition which affects the blood\'s ability to clot during an injury or bleeding episode. Patient suffering with hemophilia don\'t have as many clotting factors as there should be in the blood which leads to the longer episode of bleeding than usual. The main type of hemophilia are hemophilia A, and hemophilia B, and hemophilia A occurs due to deficiency of clotting factor VIII and hemophilia B, occurs deficiency of clotting factor IX. Hemophilia is generally treated with genetically engineered clotting factor medicines which prevent and treat prolonged bleeding. According to the Centers of Disease Control and Prevention, Hemophilia An affects 1 in 5,000 male births and around 400 babies are born with hemophilia an each year. According to the same source currently, the number of people with hemophilia in the U.S is estimated to be about 20,000. The Hemophilia Treatment Market accounted for US$ 12.45 billion in 2020 and is estimated to be US$ 22.41 billion by 2030 and is anticipated to register a CAGR of 6.1%.

Global Hemophilia Treatment Market By Dynamics

Key players launching novel drugs

In recent past key players in the market has launches novel drugs for the treatment of hemophilia; approval of such novel drugs is expected to create a lucrative opportunity for the market growth over the forecast period of time. For instance, in May 2017, Novo Nordisk received U.S. Food and Drug Administration (FDA) approval for the Biologics License Application for REBINYN (Coagulation Factor IX (Recombinant), GlycoPEGylated) indicated for the treatment of adults and children with hemophilia B. In March 2017, Bayer AG received U.S. Food and Drug Administration (FDA) approval for its factor VIII hemophilia drug namely Jivi, used in preventative treatment of hemophilia A.

Gaining approval for novel drugs

Furthermore, key players in the market are focusing on gaining approval of its novel hemophilia treatment drugs in key regions such as Europe and Asia-Pacific. Approval of such drugs in key regions is expected to fuel market growth over forecast period. For instance, in August 2018, Bayer AG’s hemophilia treatment drug Jivi received approval in Europe and in September 2018, Jivi also received approval in Japan

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Hemophilia Treatment Market By Segmentation

  The hemophilia treatment market has been segmented on the basis of drug type, recombinant coagulation factor concentrates, plasma derived coagulation factor concentrates, antifibrinolytic agents, and desmopressin.

On the basis of disease type, the hemophilia treatment market has been segmented in Hemophilia A, Hemophilia B, and Hemophilia C.

On the basis of distribution channel, the hemophilia treatment market has been segmented in retail pharmacies, online pharmacies, and hospitals.

Regional Insights:

For detailed understanding of market dynamics, the hemophilia treatment market is analyzed across key regions viz North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account major market share as compared to that of other regions. For detailed understanding of market dynamics, the global hemophilia treatment market is analyzed across key regions viz North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2029

Market representation

Revenue in USD Million & CAGR from 2020 – 2029

Market Segmentation

By Drug Type- Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Antifibrinolytic Agents, And Desmopressin

By Disease Type- Hemophilia A, Hemophilia B, Hemophilia C

By Distribution Channel- Retail Pharmacy, Online Pharmacy and Hospitals

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Detailed Segmentation:

Hemophilia Treatment Market, By Drug Type:

  • Recombinant Coagulation Factor Concentrates
    • Desmopressin
    • Antifibrinolytic Agents
    • Plasma Derived Coagulation Factor Concentrates

Hemophilia Treatment Market, By Disease Type:

  • Hemophilia A
    • Hemophilia C
    • Hemophilia B

Hemophilia Treatment Market, By Distribution Channel:

  • Retail Pharmacy
    • Hospitals
    • Online Pharmacy

Hemophilia Treatment Market, By Region:

  • North America
    • North America Hemophilia Treatment Market, By Drug Type
    • North America Hemophilia Treatment Market, By Disease Type
    • North America Hemophilia Treatment Market, By Distribution Channel
    • North America Hemophilia Treatment Market, By Country
  • U.S.
  •  Canada
      • Europe
        • Europe Hemophilia Treatment Market, By Drug Type
        • Europe Hemophilia Treatment Market, By Disease Type
        • Europe Hemophilia Treatment Market, By Distribution Channel
        • Europe Hemophilia Treatment Market, By Country
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Switzerland
  • Sweden
  • Rest of Europe
      • Asia-Pacific
        • Asia-Pacific Hemophilia Treatment Market, By Drug Type
        • Asia Pacific Hemophilia Treatment Market, By Disease Type
        • Asia-Pacific Hemophilia Treatment Market, By Distribution Channel
        • Asia-PacificHemophilia Treatment Market, By Country
  • China
  • India
  • Australia & New Zealand
  • Japan
  • South Korea
  • Rest of Asia Pacific
      • Latin America
        • Latin AmericaHemophilia Treatment Market, By Drug Type
        • Latin America Hemophilia Treatment Market, By Disease Type
        • Latin America Hemophilia Treatment Market, By Distribution Channel
        • Latin AmericaHemophilia Treatment Market, By Country
  • Brazil
  • Mexico
  • Argentina and Chile
  • Rest of Latin America
      • Middle East
        • Middle East Hemophilia Treatment Market, By Drug Type
        • Middle East Hemophilia Treatment Market, By Disease Type
        • Middle East Hemophilia Treatment Market, By Distribution Channel
        • Middle East Hemophilia Treatment Market, By Country
  • GCC
  • Israel
  • Saudi Arabia
  • UAE
  • Rest of Middle East
      • Africa
        • Africa Hemophilia Treatment Market, By Drug Type
        • Africa Hemophilia Treatment Market, By Disease Type
        • Africa Hemophilia Treatment Market, By Distribution Channel
        • Africa Hemophilia Treatment Market, By Country
  • North Africa
  • Central Africa
  • South Africa

Global Hemophilia Treatment Market By Key Players

Key players operating in the hemophilia treatment market includes Baxter International, Inc., Hospira, Inc., Baxalta, Novo Nordisk, BiogenInc., Pfizer, Inc., Bayer AG, CSL Behring, Chugai Pharmaceutical Co., Ferring B.V., Genentech, Inc., Kedrion, Octapharma AG, Sanofi SA, Shire Plc., and Swedish Orphan Biovitrum AB. In March 2017, Bayer AG received U.S. Food and Drug Administration (FDA) approval for its factor VIII hemophilia drug namely Jivi, used in preventative treatment of hemophilia A. Furthermore, key players in the market are focusing on gaining approval of its novel hemophilia treatment drugs in key regions such as Europe and Asia-Pacific. Approval of such drugs in key regions is expected to fuel market growth over forecast period. For instance, in August 2018, Bayer AG’s hemophilia treatment drug Jivi received approval in Europe and in September 2018, Jivi also received approval in Japan.

Global Hemophilia Treatment Market By Company Profile

o    Pfizer Inc.

  • Company Overview
    • Swedish Orphan Biovitrum AB
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview 
    • Shire Plc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Sanofi SA
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Octapharma AG
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Kedrion
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Genentech, Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Ferring B.V.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Chugai Pharmaceutical Co.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • CSL Behring
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Bayer AG
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Biogen Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Novo Nordisk
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Baxalta
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Hospira, Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Baxter International, Inc.
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Business Strategies Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies Overview

Global Hemophilia Treatment Market By Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Preview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Disease Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
  3. Market Dynamics Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
      • Drivers- Restraints Impact Analysis
      • PEST Analysis
      • Porter’s Five Forces Analysis
  4. Market Segmentation, By Drug Type, 2018 – 2028, (US$ Bn)
    • Introduction
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2018 — 2028
      • Y-o-Y Growth Analysis (%), 2019 – 2028
      • Segment Trends
    • Recombinant Coagulation Factor Concentrates
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Plasma Derived Coagulation Factor Concentrates
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Antifibrinolytic Agent
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Desmopressin
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
  5. Market Segmentation, By Disease Type, 2018 – 2028, (US$ Bn)
    • Introduction
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2018 — 2028
      • Y-o-Y Growth Analysis (%), 2019 – 2028
      • Segment Trends
    • Hemophilia A
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Hemophilia B
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Hemophilia C
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
  6. Market Segmentation, By Distribution Channel, 2018 – 2028, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis (%), 2019 – 2028
      • Segment Trends
    • Retail Pharmacy
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Online Pharmacy
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
    • Hospital Pharmacy
      • Introduction
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2018 – 2028
  7. Global Market, By Region, 2018 – 2028, (US$ Bn)
    • Introduction
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2018 — 2028
      • Y-o-Y Growth Analysis (%), 2019 – 2028
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Drug Type, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Country, 2018 – 2028
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast (US$ Bn), By Drug Type, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Country, 2018 – 2028
        • Brazil
        • Mexico
        • Argentina and Chile   
        • Rest of Latin America
    • Europe
      • Market Size and Forecast (US$ Bn), By Drug Type, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Country, 2018 – 2028
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Switzerland
        • Sweden
        • Rest of Europe           
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Drug Type, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Country, 2018 – 2028
        • China
        • India
        • Australia & New Zealand
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast (US$ Bn), By Drug Type, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Country, 2018 – 2028
        • GCC
        • Israel
        • Saudi Arabia
        • UAE
        • Rest of Middle East
    • Africa
      • Market Size and Forecast (US$ Bn), By Drug Type, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2018 – 2028
      • Market Size and Forecast (US$ Bn), By Country, 2018 – 2028
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Business Strategy Overview
      • Baxter International, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Business Strategy Overview
      • Hospira, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Business Strategy Overview

§  Baxalta

  1. Company Overview
  2. Product Portfolio
  3. Key Highlights
  4. Financial Overview
  5. Business Strategy Overview
  6. Novo Nordisk
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategy Overview
  7. Biogen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategy Overview
  8. Bayer AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategy Overview
  9. CSL Behring
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategy Overview
  10. Chugai Pharmaceutical Co.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategy Overview
  11. Ferring B.V.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategy Overview
  12. Genentech, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategy Overview
  13. Kedrion
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategy Overview
  14. Octapharma AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategy Overview
  15. Sanofi SA
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategy Overview
  16. Shire Plc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategy Overview
  17. Swedish Orphan Biovitrum AB
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Business Strategy Overview
  18. Analyst Views
  19. Section
    • Research Methodology
    • About Us
    • Contact

FAQs

The hemophilia treatment market has been segmented on the basis of drug type, disease type, distribution channel and region.

Key players in the market has launches novel drugs for the treatment of hemophilia are major factors driving growth of the global hemophilia treatment market.

North America is expected to account major market share as compared to that of other regions.

Key players operating in the hemophilia treatment market includes Baxter International, Inc., Hospira, Inc., Baxalta, Novo Nordisk, BiogenInc., Pfizer, Inc., Bayer AG, CSL Behring, Chugai Pharmaceutical Co., Ferring B.V., Genentech, Inc.